ISTH 2020 Congress
Hemophilia and Rare Bleeding Disorders
Theme Navigation
Abstract Number: PB0972
“Best of Both Worlds”: Combination Treatment of Desmopressin and FVIII Concentrates in Hemophilia Patients Optimizes Therapy and Reduces Costs
Abstract Number: PB1058
Case report: Inhibitor Improvement with Low Dose Immune Tolerance Induction (ITI) with rFVIIIFc and Emicizumab after Failed First Line Therapy with High Dose ITI
Abstract Number: PB0838
In vitro and in sillico Analysis of F9 Gene Missense Mutations at Exons 2 and 3 Causative of Severe Hemophilia B
Abstract Number: PB0775
In vitro Correction of Thrombin Generation by Recombinant Porcine Factor VIII (rpFVIII) in Plasma Containing Anti-Factor VIII Inhibitory Antibodies
Abstract Number: PB0821
In vitro Effect of Concizumab on Protein C Activation and Antithrombin Activity
Abstract Number: PB1041
3D Gait Analysis, Hemophilia Joint Health Score, Leg Muscle Laterality, and Biomarkers of Joint Damage: A Cross-sectional Comparative Assessment of Hemophilic Arthropathy
Abstract Number: PB1186
A Bypass Surgery with Congenital Factor 5 and Factor 8 Deficiency
Abstract Number: PB0905
A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting
Abstract Number: PB0856
A Comparative Analysis of the Immune Response to Homologous Coagulation Factors V and VIII
Abstract Number: PB1075
A Descriptive Study of Physical Activity and Fitness Level Profiles of Nigerians with Haemophila
Abstract Number: PB1196
A Digestive Hemorrhage Like No Other
Abstract Number: PB0859
A Generic Recombinant Factor VIIa Is Comparable to the Branded Novoseven in In-vitro and Pharmacokinetic Studies in Primates
Abstract Number: PB0802
A Multicenter Prospective Validation Study on Disseminated Intravascular Coagulation in Trauma-Induced Coagulopathy
Abstract Number: PB0799
A New Classification of Sepsis-Associated Disseminated Intravascular Coagulation (DIC) Based on Comprehensive Evaluation of Coagulation and Fibrinolysis
Abstract Number: PB1144
A Next Generation Recombinant Factor VIII for Subcutaneous Hemophilia A Prophylaxis
Abstract Number: LB/CO01.1
A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)